BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC Holdings

BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC is an investment fund managing more than 837.76M US dollars. The largest holdings include SpringWorks Therapeutics, Nuvalent and Mersana Therapeutics. In Q3 2022 the fund bought assets of total value of 69.8M US dollars and sold assets of total value of 85.71M US dollars.

$837.75M

portfolio value

+1.79%

quarter

-57.62%

1 year

-152.55%

3 years

BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC portfolio changes

Portfolio changes (number of shares)
Period	Buy	Sel
Q2 2018	53780000	2839000
Q3 2018	45707000	3616000
Q4 2019	178701000	15374000
Q1 2020	105451000	63759000
Q2 2020	210955000	725000
Q3 2020	177218000	4883000
Q4 2020	472397000	126747000
Q1 2021	240386000	164976000
Q2 2021	44337000	32746000
Q3 2021	371784000	142522000
Q4 2021	108130000	204144000
Q1 2022	46051000	5376000
Q2 2022	64217000	18904000
Q3 2022	69802000	85710000

BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC 13F holdings

Stock	Position type	Portfolio share	Portfolio value	Avg. open price	Current price	P/L	Last change
Biotechnology SpringWorks Therapeutics, Inc. Portfolio share: 16.45% Portfolio value: 137.83M Avg. open price: N/A Current price: $24.25 P/L: N/A Sold -17.15% shares Q3 2021	share	16.45%	137.83M	N/A	$24.25	N/A	Sold -17.15% shares Q3 2021
Biotechnology Nuvalent, Inc. Portfolio share: 7.95% Portfolio value: 66.64M Avg. open price: N/A Current price: $34.16 P/L: N/A N/A Q3 2021	share	7.95%	66.64M	N/A	$34.16	N/A	N/A Q3 2021
Biotechnology Mersana Therapeutics, Inc. Portfolio share: 6.99% Portfolio value: 58.56M Avg. open price: $7.36 Current price: $7.05 P/L: -4.22% Bought +32.84% shares Q2 2022	share	6.99%	58.56M	$7.36	$7.05	-4.22%	Bought +32.84% shares Q2 2022
Biotechnology Arcutis Biotherapeutics, Inc. Portfolio share: 6.84% Portfolio value: 57.33M Avg. open price: N/A Current price: $17.35 P/L: N/A Sold -24.61% shares Q2 2022	share	6.84%	57.33M	N/A	$17.35	N/A	Sold -24.61% shares Q2 2022
Drug Manufacturers—Specialty & Generic Dynavax Technologies Corporation Portfolio share: 6.75% Portfolio value: 56.53M Avg. open price: $5.38 Current price: $12.3 P/L: +128.79% Sold -35.65% shares Q3 2022	share	6.75%	56.53M	$5.38	$12.3	+128.79%	Sold -35.65% shares Q3 2022
Biotechnology EQRx, Inc. Portfolio share: 5.91% Portfolio value: 49.51M Avg. open price: N/A Current price: $3.46 P/L: N/A N/A Q4 2021	share	5.91%	49.51M	N/A	$3.46	N/A	N/A Q4 2021
Biotechnology Crinetics Pharmaceuticals, Inc. Portfolio share: 5.41% Portfolio value: 45.28M Avg. open price: $18.41 Current price: $18.32 P/L: -0.47% Bought +13.59% shares Q2 2022	share	5.41%	45.28M	$18.41	$18.32	-0.47%	Bought +13.59% shares Q2 2022
Biotechnology Third Harmonic Bio, Inc. Portfolio share: 5.16% Portfolio value: 43.25M Avg. open price: N/A Current price: $22 P/L: N/A N/A Q3 2022	share	5.16%	43.25M	N/A	$22	N/A	N/A Q3 2022
Biotechnology Amylyx Pharmaceuticals, Inc. Portfolio share: 3.44% Portfolio value: 28.80M Avg. open price: N/A Current price: $38.55 P/L: N/A Sold -47.48% shares Q3 2022	share	3.44%	28.80M	N/A	$38.55	N/A	Sold -47.48% shares Q3 2022
Medical Devices Rapid Micro Biosystems, Inc. Portfolio share: 3.25% Portfolio value: 27.24M Avg. open price: N/A Current price: $1.88 P/L: N/A N/A Q3 2021	share	3.25%	27.24M	N/A	$1.88	N/A	N/A Q3 2021
Biotechnology Cara Therapeutics, Inc. Portfolio share: 2.96% Portfolio value: 24.78M Avg. open price: N/A Current price: $12.49 P/L: N/A N/A Q2 2022	share	2.96%	24.78M	N/A	$12.49	N/A	N/A Q2 2022
Biotechnology Pharvaris N.V. Portfolio share: 2.91% Portfolio value: 24.39M Avg. open price: N/A Current price: $2.02 P/L: N/A N/A Q1 2021	share	2.91%	24.39M	N/A	$2.02	N/A	N/A Q1 2021
Biotechnology Nurix Therapeutics, Inc. Portfolio share: 2.84% Portfolio value: 23.75M Avg. open price: $14.01 Current price: $12.38 P/L: -11.63% Bought +41.93% shares Q2 2022	share	2.84%	23.75M	$14.01	$12.38	-11.63%	Bought +41.93% shares Q2 2022
Biotechnology Annexon, Inc. Portfolio share: 2.66% Portfolio value: 22.26M Avg. open price: $3.77 Current price: $5.74 P/L: +52.25% Bought +11.11% shares Q3 2022	share	2.66%	22.26M	$3.77	$5.74	+52.25%	Bought +11.11% shares Q3 2022
Biotechnology 2seventy bio, Inc. Portfolio share: 2.45% Portfolio value: 20.5M Avg. open price: $25.92 Current price: $15.36 P/L: -40.74% Bought +685.37% shares Q1 2022	share	2.45%	20.5M	$25.92	$15.36	-40.74%	Bought +685.37% shares Q1 2022
Biotechnology Protagonist Therapeutics, Inc. Portfolio share: 2.27% Portfolio value: 19.05M Avg. open price: N/A Current price: $7.8 P/L: N/A N/A Q2 2022	share	2.27%	19.05M	N/A	$7.8	N/A	N/A Q2 2022
Biotechnology Savara Inc. Portfolio share: 2.15% Portfolio value: 18.01M Avg. open price: $1.15 Current price: $1.64 P/L: +42.61% Bought +126.62% shares Q1 2021	share	2.15%	18.01M	$1.15	$1.64	+42.61%	Bought +126.62% shares Q1 2021
Biotechnology C4 Therapeutics, Inc. Portfolio share: 1.72% Portfolio value: 14.40M Avg. open price: $44.68 Current price: $8.28 P/L: -81.47% Bought 0.00% shares Q4 2021	share	1.72%	14.40M	$44.68	$8.28	-81.47%	Bought 0.00% shares Q4 2021
Biotechnology Atea Pharmaceuticals, Inc. Portfolio share: 1.69% Portfolio value: 14.14M Avg. open price: N/A Current price: $4.67 P/L: N/A Sold -32.82% shares Q4 2021	share	1.69%	14.14M	N/A	$4.67	N/A	Sold -32.82% shares Q4 2021
Biotechnology X4 Pharmaceuticals, Inc. Portfolio share: 1.30% Portfolio value: 10.92M Avg. open price: $2.24 Current price: $1.29 P/L: -42.52% Bought +111.60% shares Q3 2022	share	1.30%	10.92M	$2.24	$1.29	-42.52%	Bought +111.60% shares Q3 2022
Biotechnology ACADIA Pharmaceuticals Inc. Portfolio share: 1.19% Portfolio value: 9.98M Avg. open price: $14.09 Current price: $15.24 P/L: +8.16% Bought +1.67% shares Q3 2022	share	1.19%	9.98M	$14.09	$15.24	+8.16%	Bought +1.67% shares Q3 2022
Biotechnology Marinus Pharmaceuticals, Inc. Portfolio share: 1.14% Portfolio value: 9.51M Avg. open price: $24.5 Current price: $4.63 P/L: -81.10% N/A Q1 2021	share	1.14%	9.51M	$24.5	$4.63	-81.10%	N/A Q1 2021
Biotechnology Xilio Therapeutics, Inc. Portfolio share: 0.97% Portfolio value: 8.16M Avg. open price: N/A Current price: $2.43 P/L: N/A N/A Q4 2021	share	0.97%	8.16M	N/A	$2.43	N/A	N/A Q4 2021
Biotechnology Syros Pharmaceuticals, Inc. Portfolio share: 0.83% Portfolio value: 6.97M Avg. open price: $4.47 Current price: $3.83 P/L: -14.32% N/A Q3 2022	share	0.83%	6.97M	$4.47	$3.83	-14.32%	N/A Q3 2022
Biotechnology Tango Therapeutics, Inc. Portfolio share: 0.83% Portfolio value: 6.95M Avg. open price: N/A Current price: $7.69 P/L: N/A N/A Q3 2021	share	0.83%	6.95M	N/A	$7.69	N/A	N/A Q3 2021
Biotechnology Invivyd, Inc. Portfolio share: 0.72% Portfolio value: 6.06M Avg. open price: N/A Current price: $2.13 P/L: N/A Sold -22.11% shares Q4 2021	share	0.72%	6.06M	N/A	$2.13	N/A	Sold -22.11% shares Q4 2021
Shell Companies ARYA Sciences Acquisition Corp V Portfolio share: 0.59% Portfolio value: 4.90M Avg. open price: N/A Current price: $9.97 P/L: N/A N/A Q3 2021	share	0.59%	4.90M	N/A	$9.97	N/A	N/A Q3 2021
Shell Companies BCLS Acquisition Corp. Portfolio share: 0.58% Portfolio value: 4.88M Avg. open price: N/A Current price: $10.04 P/L: N/A N/A Q4 2020	share	0.58%	4.88M	N/A	$10.04	N/A	N/A Q4 2020
Biotechnology Nautilus Biotechnology, Inc. Portfolio share: 0.51% Portfolio value: 4.24M Avg. open price: N/A Current price: $1.76 P/L: N/A N/A Q2 2021	share	0.51%	4.24M	N/A	$1.76	N/A	N/A Q2 2021
Biotechnology Solid Biosciences Inc. Portfolio share: 0.44% Portfolio value: 3.7M Avg. open price: $4.02 Current price: $6.46 P/L: +60.67% Bought +12.32% shares Q1 2021	share	0.44%	3.7M	$4.02	$6.46	+60.67%	Bought +12.32% shares Q1 2021
Biotechnology Aptinyx Inc. Portfolio share: 0.39% Portfolio value: 3.27M Avg. open price: $3.4 Current price: $0.25 P/L: -92.56% Bought +59.97% shares Q4 2020	share	0.39%	3.27M	$3.4	$0.25	-92.56%	Bought +59.97% shares Q4 2020
Shell Companies Frazier Lifesciences Acquisition Corporation Portfolio share: 0.36% Portfolio value: 3.04M Avg. open price: N/A Current price: $9.5 P/L: N/A N/A Q4 2020	share	0.36%	3.04M	N/A	$9.5	N/A	N/A Q4 2020
Biotechnology Aeglea BioTherapeutics, Inc. Portfolio share: 0.34% Portfolio value: 2.81M Avg. open price: $2.56 Current price: $0.47 P/L: -81.62% Bought +87.79% shares Q2 2022	share	0.34%	2.81M	$2.56	$0.47	-81.62%	Bought +87.79% shares Q2 2022
Biotechnology Syros Pharmaceuticals, Inc. Portfolio share: 0.00% Portfolio value: 0 Avg. open price: $4.47 Current price: $3.83 P/L: -14.32% Sold -100.00% shares Q3 2022	share	0.00%	0	$4.47	$3.83	-14.32%	Sold -100.00% shares Q3 2022
Shell Companies Research Alliance Corp. II Portfolio share: 0.00% Portfolio value: 0 Avg. open price: N/A Current price: $10.11 P/L: N/A Sold -100.00% shares Q3 2022	share	0.00%	0	N/A	$10.11	N/A	Sold -100.00% shares Q3 2022
Shell Companies ARYA Sciences Acquisition Corp IV Portfolio share: 0.00% Portfolio value: 0 Avg. open price: N/A Current price: $10.05 P/L: N/A Sold -100.00% shares Q3 2022	share	0.00%	0	N/A	$10.05	N/A	Sold -100.00% shares Q3 2022
Shell Companies Panacea Acquisition Corp. II Portfolio share: 0.00% Portfolio value: 0 Avg. open price: N/A Current price: $9.93 P/L: N/A Sold -100.00% shares Q3 2022	share	0.00%	0	N/A	$9.93	N/A	Sold -100.00% shares Q3 2022

Showing TOP 37 BAIN CAPITAL LIFE SCIENCES INVESTORS's 13F holdings.

Frequently Asked Questions (FAQ)

What is the biggest position of BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC?

The biggest position of the BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC is SpringWorks Therapeutics, Inc. (SWTX) with 16.45% portfolio share worth of 137.84M US dollars.

Top 5 BAIN CAPITAL LIFE SCIENCES INVESTORS's holdings represent 44.99% of the portfolio:

SpringWorks Therapeutics, Inc. (SWTX) – 16.45%
Nuvalent, Inc. (NUVL) – 7.95%
Mersana Therapeutics, Inc. (MRSN) – 6.99%
Arcutis Biotherapeutics, Inc. (ARQT) – 6.84%
Dynavax Technologies Corporation (DVAX) – 6.75%

Who is the portfolio manager of BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC?

The portfolio manager of the BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC is .

What is the total asset value of the BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC portfolio?

BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC total asset value (portfolio value) is 837.76M US dollars.

Who is ?

is the portfolio manager of the BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC.

What is (BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC) fund performance?

BAIN CAPITAL LIFE SCIENCES INVESTORS's quarterly performance is +1.79%, annualy -57.62%. In the past 3 years, the value of 's portfolio has decreased by -153%.

What is the BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC CIK?

BAIN CAPITAL LIFE SCIENCES INVESTORS's Central Index Key is 0001703031 .